• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home The Classics Cardiology Classics

The SEPSISPAM trial: Mean arterial pressure targets in septic shock [Classics Series]

byDeepti Shroff
June 17, 2022
in Cardiology Classics, The Classics
Reading Time: 2 mins read
ABCD2 Score: Predicting Early Stroke Risk After Transient Ischemic Attack (TIA) [Classics Series]
Share on FacebookShare on Twitter

This study summary is an excerpt from the book 2 Minute Medicine’s The Classics in Medicine: Summaries of the Landmark Trials

1. This trial demonstrated that mortality did not differ with a mean arterial pressure (MAP) target of 80-85mmHg (36.6%) as compared to 65-70mmHg (34.0%) in septic shock patients.

2. Incidence of new atrial fibrillation was significantly increased in the 80-85mmHg MAP threshold group.

Original Date of Publication: April 2014

Study Rundown: The Sepsis and Mean Arterial Pressure (SEPSISPAM) trial compared a resuscitation target MAP of 80-85mmHg to a target of 65-70mmHg in septic shock patients. The primary end point measured was all-cause mortality measured at 28 days after resuscitation, which did not differ significantly between groups. Secondary outcomes of 90-day mortality and serious adverse events also did not differ between groups. Although, new onset atrial fibrillation and need for renal-replacement in chronic hypertension patients was increased in the 80-85mmHg target group. The limitations of the present study included variations in MAP during treatment as well as differential use of glucocorticoids between patients. Although, MAP fluctuation was not significant enough to warrant a protocol violation. The SEPSISPAM trial was the first to demonstrate that low versus high MAP targets in septic shock patients do not impact mortality following resuscitation.

Click to read the study in NEJM

RELATED REPORTS

The mortality in-hospital for patients undergoing elective catheter ablation for atrial fibrillation is low

Resuscitative endovascular balloon occlusion of the aorta may not improve outcomes in adults with non-traumatic out-of-hospital cardiac arrest

Terlipressin is effective in maintaining mean arterial pressure in refractory septic shock but does not improve mortality

In-Depth [randomized control trial]: The SEPISPAM trial included patients who required resuscitation for septic shock, randomizing participants into a target MAP of 80-85 mmHg (n = 142) as compared to 65-70 mmHg (n = 132). The primary outcome of all-cause mortality at 28 days did not differ in the high target group as compared to the low target group (HR 1.07; 95%CI 0.84-1.38), which was sustained at 90 days (HR 1.04; 95%CI 0.83-1.30). Conversely, the high threshold groups had significantly higher rates of new atrial fibrillation (p = 0.02) and need for renal-replacement therapy in participants with chronic hypertension (p = 0.04). Serious adverse events did not differ between groups (p = 0.64).

Asfar P, Meziani F, Hamel J-F, Grelon F, Megarbane B, Anguel N, et al. High versus Low Blood-Pressure Target in Patients with Septic Shock. New England Journal of Medicine. 2014 Apr 24;370(17):1583–93.

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: atrial fibrillaionmean arterial pressureresuscitationseptic shock
Previous Post

High burden of persistent symptoms seen in patients after COVID-19 recovery

Next Post

Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

RelatedReports

Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
Cardiology

The mortality in-hospital for patients undergoing elective catheter ablation for atrial fibrillation is low

September 4, 2026
Antiarrhythmic drugs have no survival benefit in shock-refractory out-of-hospital cardiac arrest
Cardiology

Resuscitative endovascular balloon occlusion of the aorta may not improve outcomes in adults with non-traumatic out-of-hospital cardiac arrest

May 14, 2026
Obstetric scoring systems overestimate cases of severe sepsis
Emergency

Terlipressin is effective in maintaining mean arterial pressure in refractory septic shock but does not improve mortality

January 13, 2026
UTI associated with increased risk of preeclampsia
Weekly Rewinds

2 Minute Medicine Rewind Oct 27, 2025

January 13, 2026
Next Post
Genetic risk assessment for Alzheimer’s disease does not increase anxiety, depression or stress

Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

Social networks play key roles in parental vaccination decisions

The ZF2001 vaccine is safe and effective at preventing COVID-19 in adults

Thrombophilia-associated stillbirth risk appears limited to factor V Leiden

2 Minute Medicine Rewind June 20, 2022

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • The use of neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer may reduce mortality
  • Alcohol use declines but remains above pre-pandemic levels
  • High maternal egg-peanut intake not associated with reduced infant allergy
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.